ASCO GI 2023 | Analysis of HLA gene expression in dMMR/MSI-H, ICI-resistant CRC

Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, discusses the results of a study that sought to elucidate the role of expression of HLA genes and beta-2 microglobulin (β2M) as determinants of innate resistance to immune checkpoint inhibitors (ICIs) in patients with high microsatellite instability (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer (CRC). Elevated expression of HLA genes involved in formation of the MHC-II complex was identified as a potential biomarker of improved response to immunotherapy in an analysis of a clinico-genomic database. These findings, if further validated, may optimize patient selection for ICI in CRC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.